Emily S Zhang, Samuel Doty, Neil Woody, Danielle Bottalico, Jamie A Ku, Brandon Prendes, Shlomo A Koyfman, Shauna R Campbell, Natalie Silver, Joseph Scharpf, Eric D Lamarre
{"title":"Outcomes in Minor Salivary Gland Tumors-A 20+ Year Tertiary-Care Center Experience.","authors":"Emily S Zhang, Samuel Doty, Neil Woody, Danielle Bottalico, Jamie A Ku, Brandon Prendes, Shlomo A Koyfman, Shauna R Campbell, Natalie Silver, Joseph Scharpf, Eric D Lamarre","doi":"10.1002/oto2.70030","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Minor salivary gland carcinomas are challenging to study due to their rarity and heterogeneity. We aim to further characterize clinical characteristics, treatment, and outcomes over 20 years within a single institution.</p><p><strong>Study design: </strong>Retrospective chart review was conducted on 210 patients who received primary treatment for minor salivary gland malignancy from 2000 to 2022.</p><p><strong>Setting: </strong>Single tertiary-care center.</p><p><strong>Methods: </strong>Multivariable Cox proportional hazards method was used to examine the relationship between pre-determined clinically important variables and outcomes.</p><p><strong>Results: </strong>Five-year overall survival was 77.8% (72.0-84.1). Advanced clinical T stage portended over a 2 times higher risk of death and recurrence. High pathologic grade was associated with a near 3 times higher risk of death and recurrence. There was a predominance of occult nodal metastases in level II for oral cavity and oropharynx site tumors.</p><p><strong>Conclusion: </strong>Clinical T stage and grade were important for overall survival, local, regional, and distant recurrence-free survival. Occult nodal metastases occurred most often in level II.</p>","PeriodicalId":19697,"journal":{"name":"OTO Open","volume":"8 4","pages":"e70030"},"PeriodicalIF":1.8000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11459202/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OTO Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/oto2.70030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Minor salivary gland carcinomas are challenging to study due to their rarity and heterogeneity. We aim to further characterize clinical characteristics, treatment, and outcomes over 20 years within a single institution.
Study design: Retrospective chart review was conducted on 210 patients who received primary treatment for minor salivary gland malignancy from 2000 to 2022.
Setting: Single tertiary-care center.
Methods: Multivariable Cox proportional hazards method was used to examine the relationship between pre-determined clinically important variables and outcomes.
Results: Five-year overall survival was 77.8% (72.0-84.1). Advanced clinical T stage portended over a 2 times higher risk of death and recurrence. High pathologic grade was associated with a near 3 times higher risk of death and recurrence. There was a predominance of occult nodal metastases in level II for oral cavity and oropharynx site tumors.
Conclusion: Clinical T stage and grade were important for overall survival, local, regional, and distant recurrence-free survival. Occult nodal metastases occurred most often in level II.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
